MECR
Enoyl-[acyl-carrier-protein] reductase, mitochondrial
Protein Summary
Catalyzes the NADPH-dependent reduction of trans-2-enoyl thioesters in mitochondrial fatty acid synthesis (fatty acid synthesis type II). Fatty acid chain elongation in mitochondria uses acyl carrier protein (ACP) as an acyl group carrier, but the enzyme accepts both ACP and CoA thioesters as substrates in vitro. Has a preference for short and medium chain substrates, including trans-2-hexenoyl-CoA (C6), trans-2-decenoyl-CoA (C10), and trans-2-hexadecenoyl-CoA (C16). The protein encoded by this gene is an oxidoreductase that catalyzes the last step in mitochondrial fatty acid synthesis. Defects in this gene are a cause of childhood-onset dystonia and optic atrophy. [provided by RefSeq, Mar 2017]
- ENST00000263702
- ENSP00000263702
- ENSG00000116353
- ENST00000373791
- ENSP00000362896
- NBRF1
- ETR1
- NRBF1
- CGI-63
- FASN2B
- DYTOABG
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor binding site profile | 0.77 | ||
protein domain | 0.73 | ||
cell type or tissue | 0.69 | ||
histone modification site profile | 0.65 | ||
microRNA | 0.55 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 90.19 (req: < 5)
Gene RIFs: 8 (req: <= 3)
Antibodies: 161 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 90.19 (req: >= 5)
Gene RIFs: 8 (req: > 3)
Antibodies: 161 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 4
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0